Guardian Pharmacy Services, Inc.
NYSE:GRDNMedical - Distribution
+$0.17 today
- Market cap
- $3.09B
- Beta
- 0.08
- P/E (TTM)
- 52.0
- EPS (TTM)
- $0.84
Volume 0.45M
Average 0.48M
GRDN Net Income
Bottom-line profit after all expenses, interest, and taxes.
Guardian Pharmacy Services, Inc.NYSE: GRDN
Net Income · Q2 FY2026 · quarter ended Jun 2026
Net income grows, but more slowly than its trailing trend
Q2 FY2026 net income of $21.87M rose 142.2% year over year, behind the +180.2% change in trailing-twelve-month net income. Sequentially, it rose 64.5% from the prior quarter. Over 3 fiscal years it compounded at +11.6% a year.
Context
- Net income amounted to 3.4% of revenue in FY2025, down 3.7 pp from a year earlier.
- Net income increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 5 analysts of $86.68M (+76.1%) for the fiscal year ending Dec 2026, a slowdown from the +156.4% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- $21.87M+64.5% QoQ
- Last fiscal yearDec 2025
- $49.22M+156.4% YoY
- LTMJun 2026
- $65.91M+180.2% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +142.2% | +104.8% | -37.4 pp |
| 1 year | +156.4% | +76.1% | -80.3 pp |
| 3-year CAGR | +11.6% | +29.9% | +18.3 pp |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the income statement
- Latest · FY2025
- 49.22M USD
- Year-over-year change
- +156.4%
- 4-year CAGR
- +31.8%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 49.22M | +156.4% |
| FY2024 | 2024-12-31 | (87.29M) | -465.2% |
| FY2023 | 2023-12-31 | 23.9M | -32.5% |
| FY2022 | 2022-12-31 | 35.42M | +117.1% |
| FY2021 | 2021-12-31 | 16.31M | — |
Net Income vs competitors
How GRDN compares with its peers on the latest reported figures
- GRDN's LTM Jun 2026 net income of $65.91M is the 4th highest of the 11 companies compared; the peer median is -$84.78M.
- Its year-over-year change of +180.2% is the 2nd highest of 11, against a peer median of +2.3%.
- Net income amounts to 4.5% of revenue for GRDN, versus a peer median of 31.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $1.01B | +742.1% | — | — | |
| LTM Sep 2026 | $150.09M | -7.5% | +35.6% | 7.7% | |
| LTM Sep 2026 | $114.66M | +13.2% | +74.9% | 7.2% | |
GRDNGuardian Pharmacy Services, Inc. | LTM Jun 2026 | $65.91M | +180.2% | +11.6% | 4.5% |
| LTM Jun 2026 | -$57.5M | +43.7% | — | 47.8% | |
| LTM Sep 2026 | -$67.08M | +12.1% | — | 10.8% | |
| LTM Mar 2026 | -$102.47M | -13.6% | — | 31.8% | |
| LTM Mar 2026 | -$114.48M | -47.3% | — | 529.7% | |
| LTM Sep 2026 | -$130.2M | -67.6% | — | 28.3% | |
| LTM Jun 2026 | -$149.83M | +26.2% | — | 88.2% | |
| LTM Mar 2026 | -$1.21B | -237.6% | — | 45.6% | |
| Peer median (excluding GRDN) | -$84.78M | +2.3% | +55.2% | 31.8% | |
Competitors are the stored peer set for GRDN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 792.07M | 908.91M | 1.05B | 1.23B | 1.45B |
| Cost of Revenue | 630.81M | 723.04M | 837.88M | 984.04M | 1.17B |
| Gross Profit | 161.27M | 185.87M | 208.31M | 244.37M | 282.04M |
| Gross Margin | 20.4% | 20.4% | 19.9% | 19.9% | 19.5% |
| Research & Development | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 131.12M | 133.88M | 167.36M | 307.29M | 193.13M |
| Operating Expenses | 131.12M | 133.88M | 167.36M | 307.29M | 193.13M |
| Depreciation & Amortization | 16.53M | 16.56M | 18.23M | 19.77M | 22.34M |
| EBITDA | 46.49M | 68.15M | 58.81M | (43.43M) | 96.42M |
| EBITDA Margin | 5.9% | 7.5% | 5.6% | -3.5% | 6.7% |
| Operating Income | 30.15M | 51.99M | 40.95M | (62.92M) | 88.91M |
| Operating Margin | 3.8% | 5.7% | 3.9% | -5.1% | 6.1% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 1.64M | 1.93M | 2.86M | 3.28M | 665K |
| Other Income / Expenses | (1.82M) | (2.33M) | (3.23M) | (3.56M) | (15.49M) |
| Income Before Tax | 28.33M | 49.66M | 37.72M | (66.48M) | 73.42M |
| Pre-Tax Margin | 3.6% | 5.5% | 3.6% | -5.4% | 5.1% |
| Income Tax Expense | 0 | 0 | 0 | 4.56M | 24.47M |
| Net Income | 16.31M | 35.42M | 23.9M | (87.29M) | 49.22M |
| Net Margin | 2.1% | 3.9% | 2.3% | -7.1% | 3.4% |
| EPS (Basic) | 0.27 | 0.58 | 0.39 | (1.77) | 0.79 |
| EPS (Diluted) | 0.27 | 0.58 | 0.39 | (1.77) | 0.78 |
| Weighted Avg Shares | 60.84M | 60.84M | 60.84M | 62.01M | 62.39M |
| Weighted Avg Shares (Diluted) | 60.84M | 60.84M | 60.84M | 62.01M | 63.3M |
Guardian Pharmacy Services, Inc.
NYSE:GRDN
Intrinsic Alpha fair value
Locked
Current Price
$48.84
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.